Dr Reddy’s submits Abatacept Biosimilar BLA to USFDA for review
351(k) Biologics License Application for DRL_AB IV infusion targets rheumatoid arthritis, psoriatic arthritis and pJIA
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Dr Reddy’s Laboratories acquires Progynova and Cyclo-Progynova trademarks from Mercury Pharma for…
Acquisition strengthens gynaecology portfolio and marks entry into hormone replacement therapy segment
Industry calls Union Budget 2026 a defining moment for India’s biopharma future
Industry stakeholders view the Union Budget 2026 as a pivotal inflection point in India’s life sciences journey. With the launch…
Senores Pharmaceuticals launches Deferiprone Tablets USP in the U.S.
The product will be marketed by Dr Reddy’s Laboratories
AI compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging AI across nearly every aspect…
Turning the tariff tight spot into a sweet spot
US President Trump's fresh salvo of 100 per cent tariffs on branded or patented pharmaceutical products not ‘Made in America’…
Panel Discussion: Biologics and biosimilars: The next leap in patient-centric drug development
The panel discussion titled ‘Biologics and Biosimilars: The Next Leap in Patient-Centric Drug Development’ at the FDD Conclave…
Panel Discussion: Accelerating OSD innovation: From R&D to market
The first panel discussion at FDD Conclave 2025 was on ‘Accelerating OSD innovation: From R&D to Market’. It set the tone for…
Alvotech and Dr Reddy’s Laboratories partner to develop biosimilar for Keytruda targeting global…
Collaboration aims to accelerate development and commercialisation of pembrolizumab biosimilar, expanding access to cancer…
Dr Reddy’s expands partnership with Sanofi to launch Beyfortus for RSV prevention in India
Dr Reddy’s to promote and distribute nirsevimab-based drug Beyfortus for RSV in newborns and infants